Cargando…
The Prognostic Significance of Tumor-Infiltrating Lymphocytes, PD-L1, BRCA Mutation Status and Tumor Mutational Burden in Early-Stage High-Grade Serous Ovarian Carcinoma—A Study by the Spanish Group for Ovarian Cancer Research (GEICO)
Early stages are under-represented in studies on the molecular and immune features of high-grade serous ovarian carcinoma (HGSOC), and specific studies focused on early-stage HGSOC are required for a better prognostic stratification and to personalize chemotherapy. The aim of this study was to deter...
Autores principales: | Pizarro, David, Romero, Ignacio, Pérez-Mies, Belén, Redondo, Andrés, Caniego-Casas, Tamara, Carretero-Barrio, Irene, Cristóbal, Eva, Gutiérrez-Pecharromán, Ana, Santaballa, Ana, D’Angelo, Emanuela, Hardisson, David, Vieites, Begoña, Matías-Guiu, Xavier, Estévez, Purificación, Guerra, Eva, Prat, Jaime, Poveda, Andrés, López-Guerrero, José Antonio, Palacios, José |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342764/ https://www.ncbi.nlm.nih.gov/pubmed/37446361 http://dx.doi.org/10.3390/ijms241311183 |
Ejemplares similares
-
Rucaparib for PARP inhibitor-pretreated ovarian cancer: A GEICO retrospective subgroup analysis from the Spanish Rucaparib Access Program
por: Yubero, Alfonso, et al.
Publicado: (2023) -
Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain – A GEICO study
por: Yubero, Alfonso, et al.
Publicado: (2022) -
Efficacy and safety of trabectedin in metastatic uterine leiomyosarcoma: A retrospective multicenter study of the Spanish ovarian cancer research group (GEICO)
por: Rubio, María Jesús, et al.
Publicado: (2020) -
SEOM-GEICO clinical guidelines on endometrial cancer (2021)
por: Barretina-Ginesta, María Pilar, et al.
Publicado: (2022) -
GEICO1601-ROLANDO: a multicentric single arm Phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer
por: Perez-Fidalgo, J Alejandro, et al.
Publicado: (2019)